Showing 1091-1100 of 6040 results for "".
Joel Schlessinger MD Discusses Personal Phones in the Office
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-discusses-personal-phones-in-the-office-/19276/Dealing with personal phone use at work is an issue that almost every business must consider. While it is important that people are available in case of an emergency, this rule can often be abused. In this video, Joel Schlessinger MD offers his advice on dealing with this office issue. Dr. Joel SSINON by Quantel Derma
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/sinon-by-quantel-derma/19387/The ruby laser system with active Q-switch against natural pigmentations and tattoos. The Q-switched ruby laser system SINON has a wavelength of 694 nm. It applies ultra short pulses of only 20 ns for effective treatments even with low fluency. Thus, SINON is fast, reliable and gentle and able to rNew Clinical Guidelines for Nonmelanoma Skin Cancer Treatment; Arctics Biotherapeutics Seeks New FDA Approval for ZORYVE Foam
https://practicaldermatology.com/series/dermwire-tv/new-clinical-guidelines-for-nonmelanoma-skin-cancer-treatment-arctics-biotherapeutics-seeks-new-fda-approval-for-zoryve-foam/26745/In this week’s DermwireTV, new clinical guidelines for nonmelanoma skin cancer treatment; Arcutis Biotherapeutics seeks new FDA approval for ZORYVE foam; Practical Dermatology joins the ReachMD network; and the CEO of SofWave Medical joins us to discuss the company’s Ultrasound technology.June Issue: Melanoma Updates - Epidemiology, Diagnostics, and Treatment
https://practicaldermatology.com/issues/may-june-2025/melanoma-updates-epidemiology-diagnostics-and-treatment/35917/In this article, we review the latest changes in melanoma incidence and mortality, highlight key disparities among minority populations, and summarize emerging trends in technology and treatment that are reshaping the future of melanoma care.Study Examines Association Between Childhood BMI and Risk of Developing IMSDs
https://practicaldermatology.com/series/dermwire-tv/study-examines-association-between-childhood-bmi-and-risk-of-developing-imsds/27004/In this week's DermwireTV, a new study examines the relationship between childhood BMI and skin diseases; phase 3 data sheds new light on dupilumab’s effect on inflammatory biomarkers in pediatric AD patients; and the president and CEO of Evolus discusses trends in the injectables market.Discover Dr Boswell’s Perspective: Redefining PN and AD Through a Neuroimmune Lens
https://practicaldermatology.com/programs/nemluvio-peer-network/discover-dr-boswells-perspective-redefining-pn-and-ad-through-a-neuroimmune-lens/56421/In this Clinical Conversations newsletter, Dr Scott Boswell shares how reframing prurigo nodularis (PN) and atopic dermatitis (AD) as neuroimmune-driven conditions has shaped his clinical philosophy. He shares his 3‑step approach to patient communication, highlights real‑world treatment journeys inDWTV Extra: Consensus Statements on Genital Psoriasis
https://practicaldermatology.com/topics/psoriasis/dwtv-extra-consensus-statements-on-genital-psoriasis/37269/Jennifer Cather, MD, and Melodie Young ASN, RN, discuss recent consensus statements from the Genital Psoriasis Wellness Consortium in the Journal of the European Academy of Dermatology and Venereology Clinical Practice.Calling Out Hesitation on Systemics
https://reachmd.com/programs/practical-dermatology/calling-out-hesitation-on-systemics/35703/The latest news and updates, plus Jason E. Hawkes, MD, MS, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss why dermatologists should not be reluctant to prescribe systemic therapies, and Linda F. Stein Gold, MD, discusses the importance of an ever-expanding aNew Treatment Option for Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/new-treatment-option-for-androgenetic-alopecia/32969/Reid Waldman, MD, Co-Founder and CEO of Veradermics, discusses the prevalence of androgenetic alopecia-pattern hair loss and the company's investigational treatment candidate.Vtama Approved for AD in Adults and Children
https://practicaldermatology.com/series/dermwire-tv/vtama-approved-ad-adults-and-children/30079/In this week's DermwireTV, the FDA approves Vtama (tapinarof cream 0.1%) for atopic dermatitis in adults and children; the FDA approves Nemluvio (nemolizumab) for moderate-to-severe AD; and the president of Nuance Medical discusses the acquisition of scar treatment brand, Biocorneum.